Novel cancer drug stymied by rigid billing system
The problem is that there is no billing code for the US$373,000 Yescarta therapy in Medicare
Minneapolis
A US government reimbursement system that does not fully cover the costs for Gilead Sciences Inc's complex blood cancer therapy is partly to blame for the slow uptake of the novel life-saving treatment, according to doctors who are trying to treat patients.
Only a handful of patients have received the therapy, Yescarta, two months after its approval, while waiting lists have risen to the hundreds at the 15 cancer centres authorised to administer the treatment in the US, Bloomberg News reported last Thursday.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Starbucks points to weaker consumer as profit falls
Restaurant Brands tops estimates as Burger King overhaul pays off
Walmart to shut all health centers in US over lack of profitability
Coca-Cola raises annual sales forecast on global demand, higher prices
Dying salmon trouble Norway’s vast fish-farm industry
Fast-fashion giant Shein wants to sell skincare, toothpaste and toys, too